orchiectomy

PROCEDURE12 trials

Sponsors

NCIC Clinical Trials Group, Eastern Cooperative Oncology Group, European Organisation for Research and Treatment of Cancer - EORTC, M.D. Anderson Cancer Center, UNICANCER

Conditions

Adenocarcinoma of the ProstateCastration Levels of TestosteroneFatty LiverHypogonadismKlinefelter SyndromeMetabolic SyndromeMetastatic CancerMetastatic Prostatic Adenocarcinoma

Phase 2

Hormone Ablation Therapy, Doxorubicin, and Zoledronate With or Without Strontium 89 in Treating Patients With Androgen-Dependent Prostate Cancer and Bone Metastases

CompletedNCT00081159

M.D. Anderson Cancer CenterMetastatic Cancer, Prostate Cancer

Start: 2004-07-31End: 2014-09-30Updated: 2016-11-10

LHRH Analogue Therapy With Enzalutamide or Bicalutamide in Treating Patients With Hormone Sensitive Prostate Cancer

CompletedNCT02058706

Barbara Ann Karmanos Cancer InstituteAdenocarcinoma of the Prostate, Recurrent Prostate Cancer, Stage IV Prostate Cancer

Start: 2014-05-31End: 2021-03-01Updated: 2023-05-10

Phase 3

Bicalutamide Compared With Observation Followed by Bicalutamide Plus Either Goserelin or Orchiectomy in Treating Patients With Prostate Cancer

TerminatedNCT00014586

European Organisation for Research and Treatment of Cancer - EORTCProstate Cancer

Start: 2001-01-31Updated: 2012-09-24

Hormone Therapy With or Without Surgery or Radiation Therapy in Treating Patients With Prostate Cancer

CompletedNCT00002633

NCIC Clinical Trials GroupProstate Cancer

Start: 1995-02-08End: 2012-01-06Updated: 2020-04-03

Flutamide, Suramin, and Hydrocortisone in Treating Patients With Prostate Cancer

CompletedNCT00002881

Eastern Cooperative Oncology GroupProstate Cancer

Start: 1996-10-31Updated: 2010-11-09

Hormone Therapy and Docetaxel or Hormone Therapy Alone in Treating Patients With Metastatic Prostate Cancer

CompletedNCT00104715

UNICANCERProstate Cancer

Start: 2004-10-18End: 2015-12-15Updated: 2021-02-21

Androgen Deprivation Therapy in Treating Patients With Prostate Cancer

Peter MacCallum Cancer Centre, AustraliaProstate Cancer

Start: 2004-10-31Target: 2000Updated: 2013-08-07

Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer

RecruitingNCT03678025

SWOG Cancer Research NetworkCastration Levels of Testosterone, Metastatic Prostatic Adenocarcinoma, Stage IVA Prostate Cancer AJCC v8 +2

Start: 2018-09-24End: 2031-10-01Target: 1273Updated: 2025-09-11

Phase 4

MRI Substudy; Metabolic Changes Due to Iatrogenic Hypogonadism

CompletedNCT02102646

Herlev HospitalFatty Liver, Hypogonadism, Metabolic Syndrome +1

Start: 2014-04-30End: 2015-10-31Updated: 2015-10-28

Unknown Phase

Subcapsular Orchiectomy in Men With Klinefelter Syndrome

CompletedNCT01750632

Odense University HospitalKlinefelter Syndrome

Start: 2010-08-31End: 2014-12-31Updated: 2016-10-04

Malignant Testicular Tumors in Children: A Single Institution's 12-year Experience

CompletedNCT04826952

Chang Gung Memorial HospitalOverall Survival Rates

Start: 2020-12-01End: 2021-02-28Updated: 2021-04-01

Exogenous Sex Hormones and PONV

CompletedNCT06816355

Riverside University Health System Medical CenterPostoperative Nausea and Vomiting, Sex Hormone, Transgender

Start: 2025-02-04End: 2025-02-04Updated: 2025-02-21

Related Papers

Assessing PSA levels as prognostic of overall survival (OS) in men with metastatic hormone-sensitive prostate cancer (mHSPC).

Journal of Clinical Oncology2023-06-018 citations

The relationship between a priori defined prognostic risk groups and and overall survival (OS) in men with metastatic hormone sensitive prostate cancer (mHSPC).

Journal of Clinical Oncology2023-06-012 citations

Safety and Efficacy Study of Neoadjuvant Radiohormonal Therapy for Oligometastatic Prostate Cancer: Protocol of an Open-Label, Dose-Escalation, Single-Centre Phase I/II Clinical Trial

Cancer Control2022-08-18

Metastatic prostate cancer men’s attitudes towards treatment of the local tumour and metastasis evaluative research (IP5-MATTER): protocol for a prospective, multicentre discrete choice experiment study

BMJ Open2021-11-013 citations

Clinical Efficacy of Enzalutamide vs Bicalutamide Combined With Androgen Deprivation Therapy in Men With Metastatic Hormone-Sensitive Prostate Cancer

JAMA Network Open2021-01-2642 citations

Timing of androgen deprivation therapy for prostate cancer patients after radiation: Planned combined analysis of two randomized phase 3 trials.

Journal of Clinical Oncology2018-05-2011 citations

Randomized trial of enzalutamide versus bicalutamide in combination with androgen deprivation in metastatic hormone sensitive prostate cancer: A Prostate Cancer Clinical Trials Consortium trial.

Journal of Clinical Oncology2018-02-202 citations

Health-related quality of life for immediate versus delayed androgen-deprivation therapy in patients with asymptomatic, non-curable prostate cancer (TROG 03.06 and VCOG PR 01-03 [TOAD]): a randomised, multicentre, non-blinded, phase 3 trial.

2017-07-2843 citations

Burden of metastatic hormone-sensitive prostate cancer to identify men more likely to benefit from early docetaxel.

Journal of Clinical Oncology2017-02-206 citations

Timing of androgen-deprivation therapy in patients with prostate cancer with a rising PSA (TROG 03.06 and VCOG PR 01-03 [TOAD]): a randomised, multicentre, non-blinded, phase 3 trial.

2016-05-04160 citations

Improving the pre-screening of eligible patients in order to increase enrollment in cancer clinical trials

Trials2015-01-1523 citations

Commentary on "Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial." Gravis G, Fizazi K, Joly F, Oudard S, Priou F, Esterni B, Latorzeff I, Delva R, Krakowski I, Laguerre B, Rolland F, Théodore C, Deplanque G, Ferrero JM, Pouessel D, Mourey L, Beuzeboc P, Zanetta S, Habibian M, Berdah JF, Dauba J, Baciuchka M, Platini C, Linassier C, Labourey JL, Machiels JP, El Kouri C, Ravaud A, Suc E, Eymard JC, Hasbini A, Bousquet G, Soulie M, Medical Oncology and Biostatistics, Institut Paoli-Calmettes, Marseille, France. Lancet Oncol 2013;14(2):149-58 [Epub 2013 Jan 8].

2013-11-013 citations

Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial.

2013-01-08501 citations

Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial.

2011-11-02404 citations